← Patent-cliff monitor small molecule GEMTESA VIBEGRON
Loss of exclusivity July 2042 latest FDA-listed patent expiry
Drug detail Brand name GEMTESA Active ingredient VIBEGRON Strength 75MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2020 Marketing status RX
Listed patents Patent Expires Type 12357636 July 2042 use U-4219 12102638 March 2040 use U-3045 8247415 December 2034 substance, product 12180219 March 2034 substance, product 8653260 April 2029 substance
Regulatory exclusivity Code Expires I-955 December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.